The urologist Karl-Friedrich Klippel was intensely focused on bladder cancer. He has now died at the age of 76. biosyn Arzneimittel GmbH will always hold his name in honorable remembrance. At our biotechnology corporation, the former president of the German non-profit Society of Biological Cancer Defense (Gesellschaft für Biologische Krebsabwehr e.V.) was a major force driving the development of and providing scientific support for IMMUCOTHEL, our drug for the management of superficial carcinoma of the urinary bladder, also referred to as non-muscle-invasive bladder cancer (NMIBC).
This is the second most common tumor of the urogenital tract and the fourth most common type of cancer in men. “Professor Klippel, MD mentored us on our most important studies, particularly the marketing authorization trials and gave us crucial impulses and suggestions. Thanks to his guidance, we were able to advance the subject, thereby ultimately enabling us to create the proper pharmaceutical,” said Dr. Thomas Stiefel, biosyn CEO, in commemorating the distinguished services of Professor Klippel. After his specialization in urology at Mainz, Bonn, New York and in Switzerland, he become Managing Senior Resident at the Department of Urology at Mainz University Medical Center in 1979 and was Chief Physician of the Urology Department at Celle General Hospital in Lower Saxony from 1982 to 2006.
To read more about IMMUCOTHEL: